Breast Cancer

View all Breast Cancer stories →

Both channels reported that Enhertu, a drug for a specific type of incurable breast cancer, has been made available on the NHS in England after a previous rejection on cost-effectiveness grounds. Clinical trials indicate it can extend life by about seven months on average, and around one thousand women a year are expected to benefit. The reversal came after a change in funding arrangements; BBC attributed this to a UK-US trade deal that increased medicine spending by 25%, while Sky described it as a funding arrangement. The drug had already been available in Scotland and other countries. Sky also noted it is the first targeted treatment of its kind for this cancer, and reported that charities called for approval in Wales and Northern Ireland. BBC's coverage included a patient's story and campaign efforts.

Key Claims by Channel

Tuesday 4 August 2026

Claim
Widely reported · 3 or more of 4 channels
Current breast cancer screening could miss 95% of high-risk women under 50.
The study was conducted by researchers at the University of Cambridge.	Reported by Channel 5	Not reported by BBC News	Reported by BBC One	Reported by ITV
Current screening criteria for women under 50 rely primarily on family history of breast cancer.	Reported by Channel 5	Not reported by BBC News		Reported by ITV
A new risk assessment tool identified eight times as many women who went on to develop breast cancer.	Reported by Channel 5	Not reported by BBC News
Reported by a few · 2 channels
A new risk calculator combines family history with lifestyle factors such as alcohol intake, obesity, and whether a woman has had children.	Not reported by Channel 5	Not reported by BBC News		Reported by ITV
Only 5 to 10% of breast cancer cases are linked to inherited genes.	Not reported by Channel 5	Reported by BBC News		Not reported by ITV
Using the new risk tool could lead to more false alarms and increased anxiety, and would require balancing benefits against NHS resources.	Not reported by Channel 5	Not reported by BBC News	Reported by BBC One
96% of breast cancer cases occur in women over 40.	Not reported by Channel 5		Reported by BBC One	Not reported by ITV
Only on one channel
Guidelines should consider lifestyle factors like alcohol and obesity instead of only family history.		Not reported by BBC News	Not reported by BBC One	Not reported by ITV
The NHS currently lacks the resources to support the additional women who would be identified as at risk through such a tool.	Not reported by Channel 5	Not reported by BBC News	Not reported by BBC One	Reported by ITV
73% of women under 50 who develop breast cancer within a decade had no family history.	Reported by Channel 5	Not reported by BBC News	Not reported by BBC One	Not reported by ITV
NICE stated that current evidence does not warrant a change to screening guidelines.	Not reported by Channel 5		Not reported by BBC One	Not reported by ITV
Up to a quarter of all women under 50 would be classified as high risk under the new model.	Not reported by Channel 5	Not reported by BBC News	Not reported by BBC One	Reported by ITV

Thursday 17 September 2026

Claim
Reported by all 3 channels
NHS England reversed its 2024 decision to reject Enhertu, which was initially due to cost effectiveness concerns.	Reported by Channel 5	Reported by BBC One	Reported by Sky News
Enhertu had been approved in Scotland for two years before its approval in England.	Reported by Channel 5	Reported by BBC One	Reported by Sky News
Reported by a few · 2 channels
Clinical trials showed Enhertu can extend patients' lives by about seven months compared with chemotherapy alone.	Not reported by Channel 5	Reported by BBC One	Reported by Sky News
Enhertu is now available on the NHS in England for a specific type of incurable breast cancer.	Not reported by Channel 5	Reported by BBC One	Reported by Sky News
Around one thousand women per year are expected to benefit from Enhertu's availability.	Not reported by Channel 5	Reported by BBC One	Reported by Sky News
The reversal followed a new funding arrangement, reportedly including a US trade deal with a 25% increase in medicines spending.	Not reported by Channel 5	Reported by BBC One	Reported by Sky News
Only on one channel
Wales is expected to make the drug available shortly, while the guidance does not automatically apply to Northern Ireland.	Reported by Channel 5	Not reported by BBC One	Not reported by Sky News
Enhertu is the first targeted treatment of its kind for this type of cancer.	Not reported by Channel 5	Not reported by BBC One	Reported by Sky News
Charities described the decision as monumental progress and called for the drug to be approved in Wales and Northern Ireland.	Not reported by Channel 5	Not reported by BBC One	Reported by Sky News

This is a cross-channel consensus summary, not an objective account. Consensus can be uniformly wrong, or omit what only one channel covered.